News

The companies originally entered into a commercial license and collaboration agreement in October 2011 under which Seattle Genetics had the right to exercise a co-development option for tisotumab

Merck, along with the researchers in the clinical trial service unit at the University of Oxford, reported that anacetrapib has reduced the risk of major coronary events by

The CSL subsidiary will pay an upfront payment of $91m for the acquisition. CSL Behring will get to add a pre-clinical asset in CAL-H, an HSC gene therapy

DS-5010 is a highly selective and potent RET (ret proto-oncogene) kinase inhibitor in late preclinical development. RET rearrangements and activating mutations are associated with several types of cancer,

In a separate agreement, XOMA has granted Novartis a license to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment of cardiovascular disease.

As per terms of the agreement, Gilead will pay $180.00 per Kite share in cash, representing a 29% premium to its closing price on 25 August. Based in

CF PharmTech, founded by seasoned industry experts and entrepreneurs with a successful track record in the US pharmaceutical industry, is focused on the development, manufacturing and commercialization of

Mavenclad is the first oral short-course treatment to provide efficacy across key measures of disease activity in patients with highly active RMS, including disability progression, annualized relapse rate

The Humira biosimilar can now be used in Europe for treating rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, adult and adolescent hidradenitis